新功能、新界面、新体验,扫描即可下载生物谷APP!
首页 » FDA信息 » Insmed吸入式抗生素获得FDA突破性药物认证

Insmed吸入式抗生素获得FDA突破性药物认证

来源:生物谷 2014-06-19 17:18

2014年6月19日讯 /生物谷BIOON/ --Insmed公司今年三月公布其开发的吸入式抗生素药物Arikayce进行的临床二期研究未能达到其第一预期目标,仅达到次要目标。这一消息让业界对其前景的看法出现差异。不过三个月后Insmed公司显然成功说服FDA授予他们突破性药物认证。在今年三月份的二期研究中,Arikayce未能明显降低患者体内细菌密度,但参与研究的44名患者中有11人病情好转。FDA显然认为这一证据足够有说服力。受此消息影响,公司股价也上涨32%。

从2012年开始,FDA开始对符合条件的药物授予突破性药物认证,获得这一认证的产品在研发过程中会享受到一系列的优惠措施。(生物谷Bioon.com)

详细英文报道:

After Insmed ($INSM) revealed in March that its inhaled antibiotic failed to meet the primary endpoint in a Phase II trial, more than a few analysts and market watchers looked askance at the company's plans to ask the FDA to give it a breakthrough therapy designation. But, three months later, the New Jersey biotech has prevailed upon regulators, picking up the agency's coveted guarantee of a speedy review for its well-traveled treatment.

The agency granted Insmed's request on Arikayce, or liposomal amikacin for inhalation, giving the drug a breakthrough tag for treatment-refractory nontuberculous mycobacterial lung disease, a chronic ailment that affects about 50,000 people in the U.S., the company said.

In the Phase II study, the antibiotic missed its primary of reducing in bacterial density used as a measure of infection. However, in a secondary goal, 11 of the 44 patients taking Arikayce turned in negative cultures at the end of the study, a statistically significant improvement over the placebo arm.

That was enough to sway the FDA, which, in granting the breakthrough designation, agrees to give Insmed a front-row seat in the regulatory process as it considers Arikayce's potential benefits.

The news sent Insmed's shares up about 32% on Wednesday morning, not quite enough to regain their $19.64 high before Arikayce's Phase II slip in March.

Since its institution in 2012, the FDA's breakthrough tag has led to early approvals for companies including Roche ($RHHBY), Johnson & Johnson ($JNJ) and Gilead Sciences ($GILD). But, as Novartis ($NVS) found out with its now-rejected cardio drug serelaxin, a front-row seat with regulators doesn't guarantee they'll like what they see.

Arikayce, Insmed's only drug, has endured numerous trial failures and a clinical hold in its years in development, dragging the biotech's shares up and down as it has continuously pivoted to new potential indications for its inhaled antibiotic.

 

温馨提示:87%用户都在生物谷APP上阅读,扫描立刻下载! 天天精彩!


相关标签

最新会议 培训班 期刊库